All In Biotech

Drug Trial Radar · NCT04554953

A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia

A Multi-center, Prospective Observational Study to Evaluate the Effectiveness of a Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10,877

Actual

Start

Apr 13, 2020

Primary completion

Nov 3, 2021

Study completion May 31, 2022

Sponsor

Sponsor type
Industry
First posted
Sep 18, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effectiveness of a combination drug containing fimasartan and statins on the control of hypertension and dyslipidemia, and the secondary objective is to evaluate the drug cost reduction effect, patients' satisfaction level and safety of the combination drug administration.

Conditions

  • Hypertension and Dyslipidemia

Interventions

  • Combination drug containing fimasartan and statinsDrug

    Patients who correspond to one of the following: 1. Patients who are planning to be treated with a combination drug containing fimasartan and statins after being newly diagnosed with essential hypertension and primary hypercholesterolemia 2. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension or primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB or dyslipidemia treatment that is containing a statin 3. Patients who are planning to switch to a combination drug of fimasartan and statins, among those who have been diagnosed with essential hypertension and primary hypercholesterolemia and are receiving hypertension treatment that is containing an ARB and dyslipidemia treatment that is containing a statin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood pressure controlled to the target levelTime frame: Week12
  2. LDL-C controlled to the target levelTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chonnam National University Hospital

    Gwangju, Jebong-ro, Jangseong-eup, Jangseong-gun, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.